IE Pharmaceuticals

Keenova Therapeutics PLC (MCKPF)

Track

Track

Keenova Therapeutics PLC experienced consistent buying activity from Silver Point Capital L.P. throughout early 2026. The most recent transactions occurred on May 20, 2026, involving significant share acquisitions. These purchases represent a sustained pattern of accumulation by institutional insiders, with no recorded sales during the observed period.
Ticker: MCKPF Exchange: PNK
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.8
Silver Point Capital L.P. Large shareholder
Transaction date
Purchase
Price
448.92
Quantity 83,258 +26.3%
Value US$4,084,739
2.8
Silver Point Capital L.P. Large shareholder
Transaction date
Purchase
Price
400.60
Quantity 59,032 -41.0%
Value US$1,948,595
2.8
Silver Point Capital L.P. Large shareholder
Transaction date
Purchase
Price
88.50
Quantity 275,000 +5.6%
Value US$24,337,500
2.8
Silver Point Capital L.P. Large shareholder
Transaction date
Purchase
Price
93.75
Quantity 290,000 +6.9%
Value US$27,187,500
2.8
Silver Point Capital L.P. Director Non-Executive Director
Transaction date
Proposed sale
Price
38.50
Quantity 130,000
Value US$5,005,000
0.5
Goodson Jason Daniel EVP & Head of Corp Development Officer
Transaction date
Purchase
Price
8.39
Quantity 933 +2.5%
Value US$7,823
0.5
Goodson Jason Daniel EVP & Head of Corp Development Officer
Transaction date
Purchase
Price
8.35
Quantity 200 +0.5%
Value US$1,670
1.6
SULAT JAMES R Non-Executive Director
Transaction date
Purchase
Price
8.54
Quantity 15,000 +22.2%
Value US$128,156
2.5
BISARO PAUL Non-Executive Director
Transaction date
Purchase
Price
8.47
Quantity 5,000 +7.2%
Value US$42,330
1.6
SULAT JAMES R Non-Executive Director
Transaction date
Purchase
Price
8.42
Quantity 15,000 +28.5%
Value US$126,320
0.5
Welch Stephen Andrew EVP & Head of Spec Generics Officer
Transaction date
Purchase
Price
8.48
Quantity 1,000 +2.7%
Value US$8,480
3.0
Olafsson Sigurdur O President and CEO Executive Director
Transaction date
Purchase
Price
8.37
Quantity 3,000 +1.3%
Value US$25,121
2.5
REED JOANN A Non-Executive Director
Transaction date
Sale
Price
0.12
Quantity 22,087 -100.0%
Value US$2,575
2.5
REED JOANN A Non-Executive Director
Transaction date
Sale
Price
0.12
Quantity 11,978 -35.2%
Value US$1,401
2.7
CARROLL J MARTIN Non-Executive Director
Transaction date
Sale
Price
0.40
Quantity 31,398 -100.0%
Value US$12,581
2.7
CARROLL J MARTIN Non-Executive Director
Transaction date
Sale
Price
0.40
Quantity 10,667 -100.0%
Value US$4,274
0.5
Paya Carlos V Non-Executive Director
Transaction date
Sale
Price
0.40
Quantity 16,614 -100.0%
Value US$6,715
0.5
Casey Mark J EVP and Chief Legal Officer Officer
Transaction date
Sale
Price
0.45
Quantity 15,291 -32.3%
Value US$6,881
1.0
Norton David Y Non-Executive Director
Transaction date
Sale
Price
0.40
Quantity 5,080 -100.0%
Value US$2,054
1.0
Norton David Y Non-Executive Director
Transaction date
Sale
Price
0.43
Quantity 21,807 -81.1%
Value US$9,462
0.9
CARLUCCI DAVID R Non-Executive Director
Transaction date
Sale
Price
0.14
Quantity 16,020 -100.0%
Value US$2,198
0.9
CARLUCCI DAVID R Non-Executive Director
Transaction date
Sale
Price
0.14
Quantity 31,087 -66.0%
Value US$4,483
1.0
Reasons Bryan M. EVP & CFO Officer
Transaction date
Sale
Price
0.17
Quantity 5,400 -31.8%
Value US$891
0.5
O'Neill Hugh M. EVP & Chief Comm & Ops Ofcr Officer
Transaction date
Sale
Price
0.13
Quantity 750 -0.9%
Value US$94
1.4
Russell Angus C. Non-Executive Director
Transaction date
Sale
Price
0.13
Quantity 51,789 -100.0%
Value US$6,665
0.8
Trudeau Mark President and CEO Executive Director
Transaction date
Sale
Price
0.13
Quantity 217,072 -95.0%
Value US$27,394
0.5
WATKINS IAN J EVP and Chief HR Officer Officer
Transaction date
Sale
Price
0.13
Quantity 34,581 -65.4%
Value US$4,496
0.5
Whitaker Anne Clem Non-Executive Director
Transaction date
Sale
Price
0.13
Quantity 21,087 -100.0%
Value US$2,741
0.5
YOUNGBLOOD DR KNEELAND Non-Executive Director
Transaction date
Sale
Price
0.13
Quantity 38,300 -100.0%
Value US$5,040
1.0
Reasons Bryan M. EVP & CFO
Transaction date
Purchase
Price
8.96
Quantity 5,400 +42.9%
Value US$48,383
0.8
Trudeau Mark President and CEO Executive Director
Transaction date
Purchase
Price
9.26
Quantity 2,000 +0.9%
Value US$18,528
0.8
Trudeau Mark President and CEO Executive Director
Transaction date
Planned purchase
Price
16.33
Quantity 1,000 +0.4%
Value US$16,325
0.8
Trudeau Mark President and CEO Executive Director
Transaction date
Purchase
Price
22.65
Quantity 1,000 +0.4%
Value US$22,650
Trudeau Mark President and CEO Executive Director
Transaction date
Planned purchase
Price
20.18
Quantity 1,000 +0.4%
Value US$20,180
Trudeau Mark President and CEO Executive Director
Transaction date
Planned purchase
Price
15.54
Quantity 3,000 +1.1%
Value US$46,615
Flynn James E Large shareholder
Transaction date
Sale
Price
13.74
Quantity 202,006 -2.4%
Value US$2,775,562
Flynn James E Large shareholder
Transaction date
Sale
Price
12.75
Quantity 110,922 -1.3%
Value US$1,414,256
YOUNGBLOOD DR KNEELAND
Transaction date
Purchase
Price
21.94
Quantity 4,560 +29.9%
Value US$100,046
WATKINS IAN J Chief HR Officer
Transaction date
Planned purchase
Price
21.08
Quantity 2,000 +7.5%
Value US$42,156
O'Neill Hugh M. Exec. VP & Pres, ARD
Transaction date
Planned purchase
Price
21.80
Quantity 9,000 +28.8%
Value US$196,200
REED JOANN A
Transaction date
Purchase
Price
21.50
Quantity 1,000 +6.9%
Value US$21,500
ZACCAGNINO JOSEPH A
Transaction date
Purchase
Price
21.30
Quantity 5,000 +23.7%
Value US$106,500
BOOTH MELVIN D
Transaction date
Purchase
Price
21.82
Quantity 10,000 +126.6%
Value US$218,236
Gulyas Diane H.
Transaction date
Purchase
Price
21.30
Quantity 1,500 +8.1%
Value US$31,950
Romano Steven J. Exec. VP & Chief Sci. Ofcr
Transaction date
Planned purchase
Price
21.96
Quantity 2,000 +9.0%
Value US$43,920
Trudeau Mark President and CEO Executive Director
Transaction date
Planned purchase
Price
22.28
Quantity 5,000 +1.9%
Value US$111,402
Norton David Y
Transaction date
Purchase
Price
22.02
Quantity 2,000 +35.7%
Value US$44,030
Hicks Michael-Bryant General Counsel
Transaction date
Planned purchase
Price
20.80
Quantity 7,900 +88.7%
Value US$164,309
CARROLL J MARTIN
Transaction date
Purchase
Price
20.42
Quantity 5,000 +27.1%
Value US$102,094
CARLUCCI DAVID R
Transaction date
Purchase
Price
21.83
Quantity 10,000 +62.4%
Value US$218,349
Fischer Meredith B Chief Public Affairs Officer
Transaction date
Planned purchase
Price
39.63
Quantity 1,280 +4.7%
Value US$50,725
Romano Steven J. Exec. VP & Chief Sci. Ofcr
Transaction date
Planned purchase
Price
39.88
Quantity 1,000 +4.7%
Value US$39,881
Lannum Coleman N III Sr. VP Investor Strategy & IRO
Transaction date
Purchase
Price
39.77
Quantity 1,400 +87.5%
Value US$55,678
Lannum Coleman N III Sr. VP Investor Strategy & IRO
Transaction date
Purchase
Price
39.89
Quantity 1,550 +4.9%
Value US$61,825
LLOYD RONALD K. Exec. VP & Pres, Hospital
Transaction date
Planned purchase
Price
41.26
Quantity 5,000 +38.6%
Value US$206,320
Trudeau Mark President and CEO Executive Director
Transaction date
Planned purchase
Price
40.17
Quantity 1,000 +0.4%
Value US$40,174
O'Neill Hugh M. Exec. VP & Pres, ARD
Transaction date
Planned purchase
Price
40.24
Quantity 1,000 +3.3%
Value US$40,237
Lannum Coleman N III Sr. VP Investor Strategy & IRO
Transaction date
Purchase
Price
39.33
Quantity 500 +1.6%
Value US$19,665
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-20 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
83,258 +26.3%
448.92
US$4,084,739 		83,258 +26.3% 448.92 US$4,084,739
2026-05-21 2026-05-19 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
3,356 +14.1%
481.67
US$2,210,849 		3,356 +14.1% 481.67 US$2,210,849
2026-04-17 2026-04-17 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
59,032 -41.0%
400.60
US$1,948,595 		59,032 -41.0% 400.60 US$1,948,595
2026-04-17 2026-04-15 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
275,000 +5.6%
88.50
US$24,337,500 		275,000 +5.6% 88.50 US$24,337,500
2026-01-09 2026-01-07 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
250,000 +5.3%
92.25
US$23,062,500 		250,000 +5.3% 92.25 US$23,062,500
2025-12-10 2025-12-08 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
130,974 +2.9%
88.75
US$11,623,942 		130,974 +2.9% 88.75 US$11,623,942
2025-11-19 2025-11-19 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
42,000 +0.9%
88.88
US$3,732,750 		42,000 +0.9% 88.88 US$3,732,750
2025-11-19 2025-11-17 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
26,000 +0.6%
88.88
US$2,310,750 		26,000 +0.6% 88.88 US$2,310,750
2025-11-12 2025-11-10 B Purchase
2.8
Silver Point Capital L.P.
Large shareholder
290,000 +6.9%
93.75
US$27,187,500 		290,000 +6.9% 93.75 US$27,187,500
2025-08-06 2025-08-06 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
6,700 +0.1%
92.50
US$619,750 		6,700 +0.1% 92.50 US$619,750
2025-08-06 2025-08-04 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
30,000 +0.4%
87.25
US$2,617,500 		30,000 +0.4% 87.25 US$2,617,500
2025-08-04 2025-08-01 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
50,000 +0.6%
86.50
US$4,325,000 		50,000 +0.6% 86.50 US$4,325,000
2024-07-10 2024-07-08 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
13,300 +0.4%
54.50
US$724,850 		13,300 +0.4% 54.50 US$724,850
2024-06-18 2024-06-14 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
275,000 +9.0%
52.75
US$14,506,250 		275,000 +9.0% 52.75 US$14,506,250
2024-05-29 2024-05-24 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
165,000 +5.7%
50.00
US$8,250,000 		165,000 +5.7% 50.00 US$8,250,000
2024-05-13 2024-05-09 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
350,000 +13.9%
55.50
US$19,425,000 		350,000 +13.9% 55.50 US$19,425,000
2024-05-13 2024-05-09 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
125,000 +5.2%
55.00
US$6,875,000 		125,000 +5.2% 55.00 US$6,875,000
2024-03-12 2024-03-08 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
83,000 +3.6%
43.63
US$3,620,875 		83,000 +3.6% 43.63 US$3,620,875
2024-02-20 2024-02-15 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
225,000 +10.8%
38.25
US$8,606,250 		225,000 +10.8% 38.25 US$8,606,250
2024-02-06 2024-02-02 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
20,000 +1.0%
37.55
US$751,000 		20,000 +1.0% 37.55 US$751,000
2023-12-13 2023-12-05 B Purchase
2.7
GOLDENTREE ASSET MANAGEMENT LP
Large shareholder
75,000 +3.8%
37.50
US$2,812,500 		75,000 +3.8% 37.50 US$2,812,500
2023-11-28 2023-11-15 PrS Proposed sale
2.8
Silver Point Capital L.P.

Director

Non-Executive Director
130,000
38.50
US$5,005,000 		130,000 38.50 US$5,005,000
2023-03-17 2023-03-16 B Purchase
0.5
Goodson Jason Daniel

EVP & Head of Corp Development

Officer
933 +2.5%
8.39
US$7,823 		933 +2.5% 8.39 US$7,823
2023-03-17 2023-03-16 B Purchase
0.5
Goodson Jason Daniel

EVP & Head of Corp Development

Officer
200 +0.5%
8.35
US$1,670 		200 +0.5% 8.35 US$1,670
2023-03-16 2023-03-15 B Purchase
1.6
SULAT JAMES R
Non-Executive Director
15,000 +22.2%
8.54
US$128,156 		15,000 +22.2% 8.54 US$128,156
2023-03-16 2023-03-14 B Purchase
2.5
BISARO PAUL
Non-Executive Director
5,000 +7.2%
8.47
US$42,330 		5,000 +7.2% 8.47 US$42,330
2023-03-16 2023-03-14 B Purchase
1.6
SULAT JAMES R
Non-Executive Director
15,000 +28.5%
8.42
US$126,320 		15,000 +28.5% 8.42 US$126,320
2023-03-15 2023-03-13 B Purchase
0.5
Welch Stephen Andrew

EVP & Head of Spec Generics

Officer
1,000 +2.7%
8.48
US$8,480 		1,000 +2.7% 8.48 US$8,480
2023-03-15 2023-03-13 B Purchase
3.0
Olafsson Sigurdur O

President and CEO

Executive Director
3,000 +1.3%
8.37
US$25,121 		3,000 +1.3% 8.37 US$25,121
2022-03-21 2022-03-17 S Sale
2.5
REED JOANN A
Non-Executive Director
22,087 -100.0%
0.12
US$2,575 		22,087 -100.0% 0.12 US$2,575
2022-03-21 2022-03-17 S Sale
2.5
REED JOANN A
Non-Executive Director
11,978 -35.2%
0.12
US$1,401 		11,978 -35.2% 0.12 US$1,401
2021-03-16 2021-03-12 S Sale
2.7
CARROLL J MARTIN
Non-Executive Director
31,398 -100.0%
0.40
US$12,581 		31,398 -100.0% 0.40 US$12,581
2021-03-16 2021-03-12 S Sale
2.7
CARROLL J MARTIN
Non-Executive Director
10,667 -100.0%
0.40
US$4,274 		10,667 -100.0% 0.40 US$4,274
2021-03-16 2021-03-12 S Sale
0.5
Paya Carlos V
Non-Executive Director
16,614 -100.0%
0.40
US$6,715 		16,614 -100.0% 0.40 US$6,715
2020-12-18 2020-12-17 S Sale
0.5
Casey Mark J

EVP and Chief Legal Officer

Officer
15,291 -32.3%
0.45
US$6,881 		15,291 -32.3% 0.45 US$6,881
2020-12-18 2020-12-17 S Sale
1.0
Norton David Y
Non-Executive Director
5,080 -100.0%
0.40
US$2,054 		5,080 -100.0% 0.40 US$2,054
2020-12-18 2020-12-16 S Sale
1.0
Norton David Y
Non-Executive Director
21,807 -81.1%
0.43
US$9,462 		21,807 -81.1% 0.43 US$9,462
2020-12-07 2020-12-07 S Sale
0.9
CARLUCCI DAVID R
Non-Executive Director
16,020 -100.0%
0.14
US$2,198 		16,020 -100.0% 0.14 US$2,198
2020-12-07 2020-12-04 S Sale
0.9
CARLUCCI DAVID R
Non-Executive Director
31,087 -66.0%
0.14
US$4,483 		31,087 -66.0% 0.14 US$4,483
2020-12-07 2020-12-03 S Sale
1.0
Reasons Bryan M.

EVP & CFO

Officer
5,400 -31.8%
0.17
US$891 		5,400 -31.8% 0.17 US$891
2020-11-18 2020-11-16 S Sale
0.5
O'Neill Hugh M.

EVP & Chief Comm & Ops Ofcr

Officer
750 -0.9%
0.13
US$94 		750 -0.9% 0.13 US$94
2020-11-16 2020-11-12 S Sale
1.4
Russell Angus C.
Non-Executive Director
51,789 -100.0%
0.13
US$6,665 		51,789 -100.0% 0.13 US$6,665
2020-11-16 2020-11-12 S Sale
0.8
Trudeau Mark

President and CEO

Executive Director
217,072 -95.0%
0.13
US$27,394 		217,072 -95.0% 0.13 US$27,394
2020-11-13 2020-11-11 S Sale
0.5
WATKINS IAN J

EVP and Chief HR Officer

Officer
34,581 -65.4%
0.13
US$4,496 		34,581 -65.4% 0.13 US$4,496
2020-11-10 2020-11-06 S Sale
0.5
Whitaker Anne Clem
Non-Executive Director
21,087 -100.0%
0.13
US$2,741 		21,087 -100.0% 0.13 US$2,741
2020-11-10 2020-11-06 S Sale
0.5
YOUNGBLOOD DR KNEELAND
Non-Executive Director
38,300 -100.0%
0.13
US$5,040 		38,300 -100.0% 0.13 US$5,040
2019-06-07 2019-06-07 B Purchase
1.0
Reasons Bryan M.

EVP & CFO
5,400 +42.9%
8.96
US$48,383 		5,400 +42.9% 8.96 US$48,383
2019-05-31 2019-05-30 B Purchase
0.8
Trudeau Mark

President and CEO

Executive Director
2,000 +0.9%
9.26
US$18,528 		2,000 +0.9% 9.26 US$18,528
2019-05-10 2019-05-09 PP Planned purchase
0.8
Trudeau Mark

President and CEO

Executive Director
1,000 +0.4%
16.33
US$16,325 		1,000 +0.4% 16.33 US$16,325
2019-03-06 2019-03-05 B Purchase
0.8
Trudeau Mark

President and CEO

Executive Director
1,000 +0.4%
22.65
US$22,650 		1,000 +0.4% 22.65 US$22,650
2018-12-11 2018-12-10 PP Planned purchase Trudeau Mark

President and CEO

Executive Director
1,000 +0.4%
20.18
US$20,180 		1,000 +0.4% 20.18 US$20,180
2018-05-18 2018-05-16 PP Planned purchase Trudeau Mark

President and CEO

Executive Director
3,000 +1.1%
15.54
US$46,615 		3,000 +1.1% 15.54 US$46,615
2018-05-10 2018-05-09 S Sale Flynn James E Large shareholder
202,006 -2.4%
13.74
US$2,775,562 		202,006 -2.4% 13.74 US$2,775,562
2018-05-10 2018-05-09 S Sale Flynn James E Large shareholder
110,922 -1.3%
12.75
US$1,414,256 		110,922 -1.3% 12.75 US$1,414,256
2017-11-30 2017-11-28 B Purchase YOUNGBLOOD DR KNEELAND
4,560 +29.9%
21.94
US$100,046 		4,560 +29.9% 21.94 US$100,046
2017-11-15 2017-11-14 PP Planned purchase WATKINS IAN J

Chief HR Officer
2,000 +7.5%
21.08
US$42,156 		2,000 +7.5% 21.08 US$42,156
2017-11-15 2017-11-14 PP Planned purchase O'Neill Hugh M.

Exec. VP & Pres, ARD
9,000 +28.8%
21.80
US$196,200 		9,000 +28.8% 21.80 US$196,200
2017-11-13 2017-11-13 B Purchase REED JOANN A
1,000 +6.9%
21.50
US$21,500 		1,000 +6.9% 21.50 US$21,500
2017-11-13 2017-11-13 B Purchase ZACCAGNINO JOSEPH A
5,000 +23.7%
21.30
US$106,500 		5,000 +23.7% 21.30 US$106,500
2017-11-13 2017-11-13 B Purchase BOOTH MELVIN D
10,000 +126.6%
21.82
US$218,236 		10,000 +126.6% 21.82 US$218,236
2017-11-13 2017-11-13 B Purchase Gulyas Diane H.
1,500 +8.1%
21.30
US$31,950 		1,500 +8.1% 21.30 US$31,950
2017-11-13 2017-11-13 PP Planned purchase Romano Steven J.

Exec. VP & Chief Sci. Ofcr
2,000 +9.0%
21.96
US$43,920 		2,000 +9.0% 21.96 US$43,920
2017-11-13 2017-11-10 PP Planned purchase Trudeau Mark

President and CEO

Executive Director
5,000 +1.9%
22.28
US$111,402 		5,000 +1.9% 22.28 US$111,402
2017-11-13 2017-11-10 B Purchase Norton David Y
2,000 +35.7%
22.02
US$44,030 		2,000 +35.7% 22.02 US$44,030
2017-11-13 2017-11-09 PP Planned purchase Hicks Michael-Bryant

General Counsel
7,900 +88.7%
20.80
US$164,309 		7,900 +88.7% 20.80 US$164,309
2017-11-13 2017-11-09 B Purchase CARROLL J MARTIN
5,000 +27.1%
20.42
US$102,094 		5,000 +27.1% 20.42 US$102,094
2017-11-13 2017-11-09 B Purchase CARLUCCI DAVID R
10,000 +62.4%
21.83
US$218,349 		10,000 +62.4% 21.83 US$218,349
2017-09-01 2017-08-30 PP Planned purchase Fischer Meredith B

Chief Public Affairs Officer
1,280 +4.7%
39.63
US$50,725 		1,280 +4.7% 39.63 US$50,725
2017-06-12 2017-06-09 PP Planned purchase Romano Steven J.

Exec. VP & Chief Sci. Ofcr
1,000 +4.7%
39.88
US$39,881 		1,000 +4.7% 39.88 US$39,881
2017-06-12 2017-06-09 B Purchase Lannum Coleman N III

Sr. VP Investor Strategy & IRO
1,400 +87.5%
39.77
US$55,678 		1,400 +87.5% 39.77 US$55,678
2017-06-12 2017-06-09 B Purchase Lannum Coleman N III

Sr. VP Investor Strategy & IRO
1,550 +4.9%
39.89
US$61,825 		1,550 +4.9% 39.89 US$61,825
2017-06-12 2017-06-09 PP Planned purchase LLOYD RONALD K.

Exec. VP & Pres, Hospital
5,000 +38.6%
41.26
US$206,320 		5,000 +38.6% 41.26 US$206,320
2017-06-12 2017-06-09 PP Planned purchase Trudeau Mark

President and CEO

Executive Director
1,000 +0.4%
40.17
US$40,174 		1,000 +0.4% 40.17 US$40,174
2017-06-12 2017-06-08 PP Planned purchase O'Neill Hugh M.

Exec. VP & Pres, ARD
1,000 +3.3%
40.24
US$40,237 		1,000 +3.3% 40.24 US$40,237
2017-06-07 2017-06-05 B Purchase Lannum Coleman N III

Sr. VP Investor Strategy & IRO
500 +1.6%
39.33
US$19,665 		500 +1.6% 39.33 US$19,665
Explore more

More insider trading research around Keenova Therapeutics PLC

More insider trades in IE
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity